In April 2025, the FDA granted orphan drug designation to spesolimab-sbzo for the treatment of pyoderma gangrenosum. This ...

These four Dividend Aristocrats are Buy-rated sector leaders with yields above 3%. Passive income investors can buy and hold ...

After underperforming the overall market for the past few years, large-cap pharmaceutical stocks may now be positioned to ...

InflaRx (NASDAQ:IFRX) is one of the best penny stocks under $1 to buy now. As May came to an end, InflaRx announced that its ...

Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, said: "We would like to thank the dedicated physicians and pyoderma gangrenosum patients for their participation in this ...

Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, said: “We would like to thank the dedicated physicians and pyoderma gangrenosum patients for their participation in this ...

Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, said: “We would like to thank the dedicated physicians and pyoderma gangrenosum patients for their participation in this ...

JENA, Germany, May 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that ...

Although his prognosis is still unknown — given that pyoderma gangrenosum remains poorly understood by scientists — Johns Hopkins gave Ryan the grim prediction in February that he likely has ...

Unlike many other ulcerative colitis–related skin conditions, pyoderma gangrenosum can appear even when someone's IBD is well-controlled, Dr. DeWane notes.

Pyoderma gangrenosum (PG), a rare inflammatory skin disease, had been challenging to diagnose due to its nonspecific histological characteristics. Researchers conducted a retrospective study to ...